Robust expression of EZH2 in endocervical neoplastic lesions

Evelin Makk1, Levente Bálint1, János Cifra2, Tamás Tornóczky1, Angéla Oszter1, Arnold Tóth3, Endre Kálmán1, Krisztina Kovács1

Received: 24 October 2018 / Revised: 22 February 2019 / Accepted: 25 February 2019 / Published online: 22 March 2019

Abstract
The aim of this study was to evaluate the nuclear expression of histone methyltransferase enhancer of zeste homolog 2 (EZH2) in endocervical neoplastic lesions such as invasive endocervical adenocarcinoma (ECA) and cervical in situ adenocarcinoma (AIS) in comparison with normal endocervix and non-neoplastic counterparts. A total of 54 consecutive neoplastic cases (37 ECA, 17 AIS) and 32 non-neoplastic endocervical lesions (15 reactive atypia, 9 microglandular hyperplasia, 3 tuboendometrioid metaplasia, 3 tunnel cluster, 2 endometriosis) were included in the study with adjacent normal endocervix if present. EZH2 immunoreactivity was evaluated semiquantitatively by three independent experts in lesions and adjacent normal glandular epithelium as well. EZH2 expression was defined robust if at least two of the three experts rated partial or diffuse positivity. Robust EZH2 expression was statistically compared among the neoplastic, non-neoplastic, and normal glandular epithelium samples. Diagnostic test capability of robust EZH2 expression was calculated. Fifty-three out of the 54 neoplastic cases (98%) showed robust EZH2 expression. Robust EZH2 expression was significantly less often (4 out of 32 cases, 12.5%) found in the non-neoplastic endocervical lesions (p < 0.0001) and never (0 out of 66 samples) in the adjacent normal glandular epithelium. Robust EZH2 overexpression had a sensitivity and specificity of over 95% in detecting neoplastic lesions versus non-neoplastic lesions or normal glandular epithelium. EZH2 may play a role in the pathogenesis of endocervical neoplasia, and the detection of robust expression of EZH2 might be a useful differential diagnostic tool in problematic endocervical lesions in histology and cytology as well.

Keywords Cervical cancer · EZH2 · Endocervical adenocarcinoma · AIS

Introduction
Endocervical adenocarcinoma (ECA) is the second most common histological type of cervical cancer; it comprises approximately 20 to 25% of cervical malignancies [1] and has a poorer prognosis than squamous cell carcinoma [2]. Cervical adenocarcinomas and their precursor lesions are heterogeneous and have several different subtypes, most of them closely related to HR-HPVs [3].

It is well established that the pRB pathway is involved in the pathogenesis of cervical cancer due to the interaction with HR-HPV E7 oncoproteins leading to genomic instability [4]. It is also known that viral E6/E7 oncoproteins may interact with different types of epigenetic enzymes, such as p300, CBP, and pCAF, which can be involved in the oncogenesis [5].

Enhancer of zeste homolog 2 (EZH2), a member of the polycomb group of genes, is a methyltransferase that methylates histone H3 on gene promoters and plays a critical role in epigenetic gene silencing and chromatin remodeling. EZH2 inhibits cell differentiation and targets gene expression. In conjunction with the p53 protein, it induces tumor cell proliferation, metastasis, and immortalization [6].

Recent studies focused on the role of EZH2 in the pathogenesis of various adenocarcinomas as well as malignant tumors of the breast [7], lung [8], stomach [9], colon [10], pancreatobiliary tract [11], liver [12], thyroid gland [13], prostate [14], bladder [15], uterus [16], and ovary [17]. High expression of EZH2 was shown to be associated with tumor aggressiveness and was suggested as a potential differential...
diagnostic marker [8, 10–17]. In the cervix, one study reported overexpression and the possible prognostic significance of EZH2 in squamous cell carcinoma [18].

Expression of EZH2 in endocervical neoplastic lesions is yet unknown. In this study, we examined EZH2 expression in ECA and AIS, compared with non-neoplastic cervical lesions and normal glandular epithelium.

Materials and methods

Patients and specimen collection

Consecutive patients from 2007 to 2017 with a diagnosis of endocervical neoplastic lesions (ECA and/or AIS with or without cervical intraepithelial neoplasia) and patients with benign findings as a control group were collected from the archives of the Department of Pathology, University of Pécs, Hungary, and Department of Pathology, County Hospital Tolna, János Balassa Hospital, Szekszárd, Hungary.

Formalin-fixed and paraffin-embedded tissue samples from biopsy, cone, or hysterectomy specimens were available along with the HE slides in each case. Slides were re-evaluated to select the most feasible specimens for immunohistochemistry for each patient. We classified endocervical adenocarcinomas based on the International Endocervical Adenocarcinoma Criteria and Classification (IECC) [19].

This work has been approved by the local ethical committee (number of permission: PTE/57682/2017).

Immunohistochemistry

Prior to immunohistochemistry, formalin-fixed paraffin-embedded tissue specimens were cut into 4-μm-thick sections and dried for 20 min at 60 °C.

Immunostaining was performed using Leica Bond Max autostainer (Leica Biosystems, Bannockburn, IL) and Leica Bond Polymer Refine Detection Kit (Leica Biosystems, Newcastle Upon Tyne, UK). The mouse monoclonal EZH2 antibody (clone 6A10) was obtained from Leica Biosystems (Newcastle Upon Tyne, UK) and used at a dilution of 1:200. The immunostaining protocol included deparaffinization and pH 9 epitope retrieval for 20 min, peroxidase blocking for 5 min, primary antibody incubation for 15 min, post-primary rabbit anti-mouse IgG for 8 min, polymer anti-rabbit Pol-HRP-IgG for 8 min, diaminobenzidine chromogen for 10 min, and hematoxylin counterstain for 5 min. Positive and negative controls were included in all reactions.

Evaluation of immunoreactivity

Immunoreactivity evaluation included not only the neoplastic lesions (ECA, AIS) or non-neoplastic lesions in control patients but the adjacent normal glandular epithelium as well, if present. The presence of concurrent cervical intraepithelial neoplasia was noted; however, these lesions were not included in the immunoreactivity analysis. The histological patterns were detected in the original, routine HE stained slides.

Immunoreactivity was evaluated semiquantiatively by three independent board-certified pathologists with over 15 years of professional experience (expert 1: E.K., expert 2: K.K., expert 3: A.O.). Cases were regarded as positive if they were obviously positive by × 40 magnification and further classified according to the percentage of cells with nuclear staining: < 10% as focally positive “+”, 10–50% as partly positive “++”, and > 50% as diffusely positive “+++” [20].

The inter-expert agreement was determined using Intraclass Correlation Coefficient (ICC) [21] for both the neoplastic and the non-neoplastic lesions ratings. Two-way model, absolute agreement type was applied; both single and average measurement reliability was calculated. The analysis was run in MedCalc statistical software (version 13.0.0.0, MedCalc Software bvba, Ostend, Belgium) [22].

For statistical analyses, the individual ratings per lesions and normal glandular epithelium if present were transformed into a binary overall score. Immunoreactivity of a lesion or normal glandular epithelium was regarded “robust” if at least two of the three experts rated either “++” or “+++”. Immunoreactivity was regarded as “negative/focally positive” if at least two of the three experts rated either “−” or “+”. Adjacent normal glandular epithelium was included in analyses if it was detected by at least two experts.

Neoplastic (ECA and AIS) and non-neoplastic lesion immunoreactivity overall scores were statistically compared using Fisher’s exact test (MedCalc). P value was considered statistically significant if under 0.05.

Diagnostic test capability (sensitivity, specificity, and positive and negative predictive value) of EZH2 overexpression in distinguishing (a) neoplastic lesions from non-neoplastic, (b) neoplastic lesions from normal endocervical epithelium, and (c) neoplastic lesions from non-neoplastic lesions and normal endocervical epithelium combined was evaluated also using MedCalc.

Results

A total of 54 cases of endocervical neoplastic lesions (37 ECA, 17 AIS) were retrieved from the archive. In 12 out of these cases, concurrent HSILs were present. Concurrent LSIL was present in one case. The median patient age was 44.5 (range 29–84). The most common IECC diagnoses were human papillomavirus–associated adenocarcinoma (HPVA) type (92% of the cohort). Between subcategories, usual type adenocarcinoma was the most common HPV type (88% of the cohort), followed by villoglandular, mucinous not
otherwise specified (NOS), and mucinous including intestinal and invasive stratified mucin-producing carcinoma (iSMILE) categories (3%) (Table 1). There were only three patients with nonhuman papillomavirus–associated adenocarcinoma (NHPVA) (8%). Between subcategories, there were two cases with serous type and one with the endometrioid type of NHPVA.

The detailed results of the EZH2 immunohistochemical analyses for ECA and AIS are summarized in Table 1 (for ECA) and in Table 2 (for AIS).

Table 1 Clinical and immunostaining data of ECA cases

| Case No. | Age | Diagnosis       | Type (IECC)          | EZH2 immunoreactivity | Normal glandular epithelium | Neoplastic endocervical lesions |
|---------|-----|-----------------|----------------------|-----------------------|----------------------------|---------------------------------|
|         |     |                 |                      |                       | Expert 1 | Expert 2 | Expert 3 | Expert 1 | Expert 2 | Expert 3 |
| 1.      | 83  | ECA             | HPVA/mucinous, intestinal | σ²σσσσ           | +++       | +++       | +++       |         |         |         |
| 2.      | 84  | ECA             | HPVA/usual           | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 3.      | 74  | ECA             | HPVA/usual           | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 4.      | 53  | ECA + CIN3³     | HPVA/usual           | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 5.      | 50  | ECA             | NHPVA/endoendometrioid | σσσσσσ           |         |         |         |         |         |         |
| 6.      | 48  | ECA             | HPVA/usual           | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 7.      | 49  | ECA + CIN3      | HPVA/usual           | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 8.      | 48  | ECA             | HPVA/usual           | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 9.      | 42  | ECA + AIS       | HPVA/usual           | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 10.     | 45  | ECA             | HPVA/usual           | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 11.     | 37  | ECA             | HPVA/usual           | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 12.     | 41  | ECA             | HPVA/villoglandular | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 13.     | 37  | ECA             | HPVA/usual           | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 14.     | 36  | ECA + CIN2      | HPVA/usual           | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 15.     | 30  | ECA             | HPVA/usual           | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 16.     | 31  | ECA             | HPVA/usual           | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 17.     | 90  | ECA             | HPVA/usual           | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 18.     | 43  | ECA             | HPVA/usual           | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 19.     | 43  | ECA             | HPVA/usual           | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 20.     | 49  | ECA             | HPVA/mucinous NOS⁷   | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 21.     | 44  | ECA             | HPVA/usual           | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 22.     | 47  | ECA             | HPVA/usual           | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 23.     | 32  | ECA             | HPVA/usual           | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 24.     | 42  | ECA             | HPVA/usual           | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 25.     | 37  | ECA             | HPVA/usual           | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 26.     | 54  | ECA             | HPVA/usual           | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 27.     | 52  | ECA             | HPVA/usual           | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 28.     | 50  | ECA             | HPVA/usual           | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 29.     | 36  | ECA             | HPVA/usual           | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 30.     | 86  | ECA             | HPVA/usual           | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 31.     | 45  | ECA             | HPVA/usual           | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 32.     | 36  | ECA + CIN3      | HPVA/usual           | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 33.     | 41  | ECA + AIS       | HPVA/iSMILE⁸         | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 34.     | 48  | ECA             | NHPVA/serous         | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 35.     | 77  | ECA             | NHPVA/serous         | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 36.     | 47  | ECA             | HPVA/usual           | σσσσσσ           | +++       | +++       | +++       |         |         |         |
| 37.     | 37  | ECA             | HPVA/usual           | σσσσσσ           | +++       | +++       | +++       |         |         |         |

Endocervical adenocarcinoma

¹ Cervical intraepithelial neoplasia

² No normal glandular epithelium present on slide

³ Immunoreactivity extent: +++ = > 50%, ++ = 10–50%, + = < 10%, − = negative—no obvious immunoreactivity at × 40 magnification

⁴ International Endocervical Adenocarcinoma Criteria and Classification [19]

⁵ Human papillomavirus–associated adenocarcinoma

⁶ Nonhuman papillomavirus–associated adenocarcinoma

⁷ Mucinous, not otherwise specified

⁸ Invasive stratified mucin–producing carcinoma

⁹ Overall score of immunoreactivity evaluation: “−” refers to negative/focally positive (at least two experts rated either “−” or “+”) while “+” refers to robust expression (at least two experts rated either “++” or “+++”)
All neoplastic endocervical lesions (ECA and AIS) were found to be EZH2 positive by all three experts (for details see Tables 1 and 2). Except for one case out of the 54, all of these lesions (98.14%) received a “robust” overall score.

Adjacent normal glandular epithelium was detected in 34 (63%) out of the 54 malignant cases by at least two experts. On average, immunonegativity was found in 88.3%, while focal positivity in 11.7% of the detected normal glandular epithelium samples by the three experts (for details see Tables 1 and 2). Ratings resulted in an overall score of “negative/focally positive” in all of the 34 cases.

Figure 1 shows representative cases of diffuse (robust) EZH2 immunoreactivity of the neoplastic endocervical lesions (ECA and AIS) and negative immunoreactivity of the adjacent normal glandular epithelium.

A total of 32 non-neoplastic endocervical lesions (15 reactive atypia, 9 microglandular hyperplasia, 3 tuboendometrioid metaplasia, 3 tunnel cluster, 2 endometriosis) were analyzed. The detailed results of the EZH2 immunohistochemical analyses for non-neoplastic endocervical lesions were summarized in Table 3.

On average, 67.7% of the ratings were negative, 24% of the ratings were focally positive, and 8.3% of the ratings were partly positive. The ratings resulted in an overall score of “negative/focally positive” in 28 out of the 32 cases (87.5%) and “robust” in the rest of the cases (4 cases, 12.5%).

Adjacent normal glandular epithelium was detected in all non-neoplastic endocervical lesion cases by all experts.

These adjacent normal glandular epithelium samples were on average rated immunonegative in 95.84%, focally positive in 2.08%, and partially positive in other 2.08% (for details see Table 3). These ratings resulted in an overall score of “negative/focally positive” for each sample. Figures 2 and 3 show representative cases of negative or focally positive (+) EZH2 immunoreactivity of the non-neoplastic lesions.

Fisher’s exact test yielded a statistically significant (two-tailed \( p < 0.0001 \)) difference in the overall immunoreactivity scores between the neoplastic and non-neoplastic lesions.

---

**Table 2 Clinical and immunostaining data of AIS cases**

| Case No. | Age | Diagnosis | EZH2 immunoreactivity --- | Normal glandular epithelium | Neoplastic endocervical lesions |
|----------|-----|-----------|--------------------------|-----------------------------|---------------------------------|
|          |     |           | Expert 1 | Expert 2 | Expert 3 | Expert 1 | Expert 2 | Expert 3 | Overall score 1 | Overall score 2 | Overall score 3 |
| 1. 33    | AIS | - | - | - | - | +++ | +++ | +++ | + |
| 2. 53    | AIS + CIN1 | + | + | - | - | +++ | +++ | +++ | + |
| 3. 42    | ECA + AIS | + | - | - | - | +++ | +++ | +++ | + |
| 4. 41    | AIS | - | - | - | - | +++ | +++ | +++ | + |
| 5. 38    | AIS | - | - | - | - | +++ | +++ | +++ | + |
| 6. 35    | AIS | - | - | - | - | +++ | +++ | +++ | + |
| 7. 36    | AIS | - | - | - | - | +++ | +++ | +++ | + |
| 8. 31    | AIS | - | - | - | - | +++ | +++ | +++ | + |
| 9. 45    | AIS + CIN3 | - | - | - | - | (+++) | (+++) | (+++) | + |
| 10. 48   | AIS + CIN3 | - | + | - | - | +++ | +++ | +++ | + |
| 11. 46   | AIS + CIN3 | - | - | - | - | +++ | +++ | +++ | + |
| 12. 41   | AIS + CIN3 | - | - | - | - | +++ | +++ | +++ | + |
| 13. 45   | AIS + CIN3 | - | - | - | - | +++ | +++ | +++ | + |
| 14. 40   | AIS + CIN3 | - | + | - | - | +++ | +++ | +++ | + |
| 15. 41   | ECA + AIS | - | - | - | - | +++ | +++ | +++ | + |
| 16. 38   | AIS + CIN3 | - | + | - | - | +++ | +++ | +++ | + |
| 17. 65   | AIS + CIN3 | - | - | - | - | +++ | +++ | +++ | + |

---

1. Cervical intraepithelial neoplasia
2. No normal glandular epithelium present on slide
3. Immunoreactivity extent: +++ = >50%, ++ = 10–50%, + = <10%, - = negative—no obvious immunoreactivity at × 40 magnification
4. Overall score of immunoreactivity evaluation; “−” refers to negative/focally positive (at least two experts rated either “−” or “+”) while “+” refers to robust expression (at least two experts rated either “++” or “+++”)
Robust EZH2 expression was found in 53 out of the 54 neoplastic lesions vs. in 4 out of the 32 non-neoplastic lesions.

Robust EZH2 expression was found to have a sensitivity of 98.15% (95% CI = 90.11 to 99.95%) and a specificity of 87.5% (95% CI = 71.01 to 96.49%) in distinguishing neoplastic lesions from non-neoplastic lesions, with a positive predictive value of 92.98% (95% CI = 83 to 98.05%) and a negative predictive value of 96.55% (95% CI = 82.24 to 99.91%).

A sensitivity of 98.15% (95% CI = 90.11 to 99.95%) and a specificity of 100% (95% CI = 94.4 to 100%) were found in distinguishing neoplastic lesions from all normal glandular epithelium samples ($n = 66$), with a positive predictive value of 100% (95% CI = 93.28 to 100%) and a negative predictive value of 98.46% (95% CI = 91.72 to 99.96%).

A sensitivity of 98.15% (95% CI = 90.11 to 99.95%) and a specificity of 95.88% (95% CI = 89.78 to 98.87%) were found in distinguishing neoplastic from non-neoplastic lesions and normal endocervical epithelium samples combined ($n = 98$), with a positive predictive value of 92.98% (95% CI = 83 to 98.05%) and a negative predictive value of 98.46% (95% CI = 94.17 to 99.97%).

For the neoplastic endocervical lesion (ECA and AIS) immunoreactivity ratings, inter-expert ICCs were 0.53 for single measures (95% confidence interval = 0.37–0.67) and 0.77 for average measures (95% confidence interval = 0.64–0.86).

For the non-neoplastic endocervical lesion immunoreactivity ratings, inter-expert ICCs were 0.8 for single measures (95% confidence interval = 0.68–0.89) and 0.92 for average measures (95% confidence interval = 0.86–0.96).

**Discussion**

The aim of this study was to investigate the EZH2 expression status of neoplastic endocervical lesions such as ECA and AIS compared with normal glandular epithelium and non-neoplastic endocervical lesions.

All endocervical neoplastic lesions in this study were found to be EZH2 positive by all experts. Moreover, immunoreactivity was found to be very extensive. Except for one case, all (98.14%) neoplastic lesions showed a robust EZH2 expression.

In contrast, robust EZH2 expression was significantly less often (4 out of 32 cases, 12.5%) found in the non-neoplastic glandular lesions (two-tailed $p < 0.0001$) and never (0 out of 66 samples) in the adjacent normal glandular epithelium.
Occasionally, false positivity was caused by squamous metaplasia or reserve cell hyperplasia (e.g., in Fig. 2 case b).

Robust EZH2 expression appeared to have an excellent diagnostic test capability in differentiating neoplastic lesions from non-neoplastic lesions and normal endocervical epithelium. A sensitivity of 98.15% and a specificity of 95.88% were found in distinguishing neoplastic from non-neoplastic lesions and normal endocervical epithelium samples combined ($n = 98$), with a positive predictive value of 92.98% and a negative predictive value of 98.46%.

Inter-observer agreement for average measurements could be interpreted as excellent [23].

Our presented data suggest that EZH2 plays a role in the pathogenesis of not only malignancies of the breast [7], lung

### Table 3: Clinical and immunostaining data of non-neoplastic cases

| Case No. | Age | Diagnosis                  | Normal glandular epithelium | Non-neoplastic endocervical lesions |
|----------|-----|----------------------------|-----------------------------|-------------------------------------|
|          |     |                            | Expert | Overall score | Expobre | Overall score |
| 1        | 33  | Reactive atypia            | –      | –            | –       | –             |
| 2        | 50  | –                          | –      | –            | +        | +             |
| 3        | 39  | –                          | –      | –            | –       | –             |
| 4        | 54  | –                          | –      | –            | +        | +             |
| 5        | 40  | –                          | –      | –            | +        | –             |
| 6        | 40  | –                          | –      | –            | –       | –             |
| 7        | 42  | –                          | –      | –            | –       | –             |
| 8        | 39  | +                         | –      | –            | +        | +             |
| 9        | 49  | ++                        | –      | –            | ++       | +             |
| 10       | 43  | –                         | –      | –            | +        | –             |
| 11       | 32  | –                          | –      | –            | –       | –             |
| 12       | 46  | –                          | –      | –            | +        | –             |
| 13       | 61  | –                          | –      | –            | –       | –             |
| 14       | 48  | –                          | –      | –            | –       | –             |
| 15       | 48  | –                          | –      | –            | –       | –             |
| 16       | 51  | Microglandular hyperplasia | –      | +            | –       | –             |
| 17       | 50  | –                          | –      | –            | –       | –             |
| 18       | 37  | –                          | –      | –            | –       | –             |
| 19       | 69  | –                          | –      | –            | +        | +             |
| 20       | 37  | –                          | –      | –            | –       | –             |
| 21       | 54  | –                          | –      | –            | +        | +             |
| 22       | 37  | –                          | –      | –            | –       | –             |
| 23       | 48  | –                          | –      | –            | –       | +             |
| 24       | 51  | –                          | –      | –            | –       | –             |
| 25       | 35  | Endometriosis              | –      | –            | –       | –             |
| 26       | 33  | –                          | –      | –            | –       | –             |
| 27       | 36  | TEM$^1$                    | –      | –            | –       | –             |
| 28       | 41  | +                         | –      | –            | ++       | +             |
| 29       | 46  | –                          | –      | –            | +        | –             |
| 30       | 61  | Tunnel cluster             | –      | –            | –       | –             |
| 31       | 53  | –                          | –      | +            | ++       | +             |
| 32       | 67  | –                          | –      | –            | –       | –             |

$^1$ Tuboendometrioid metaplasia

$^2$ Immunoreactivity extent: $++ = 10–50\%$, $+= <10\%$, $\approx$ = negative—no obvious immunoreactivity at $\times 40$ magnification

$^3$ Overall score of immunoreactivity evaluation: “−” refers to negative/focally positive (at least two experts rated either “−” or “+”) while “+” refers to robust expression (at least two experts rated either “++” or “+++”)
[8], stomach [9], colon [10], pancreatobiliary tract [11], liver [12], thyroid gland [13], prostate [14], bladder [15], endometrium [16], and ovary [17] but also in endocervical neoplasia as well. Since EZH2 expression was found in all investigated cases including the non-human papillomavirus–related ones, authors speculate that EZH2 is a substantial and independent factor in endocervical carcinogenesis.

Yuting Gu et al. [24] studied the expression of EZH2 in endometrial carcinomas. The expression rate of EZH2 in endometrial carcinoma tissue (68.27%) was significantly higher than that in adjacent tissue (24.03%). Nan Jia et al. [25] demonstrated that EZH2 was overexpressed (medium to strong reactivity) in complex hyperplasia, atypical hyperplasia, and endometrial cancer, but not in simple hyperplasia and normal endometrium (with negative to weak expression). Although these studies investigated immunoreactivity intensity, unlike immunoreactivity extent as in the present study, the results appear to be still comparable. EZH2 immunoreactivity differences between neoplastic and non-neoplastic and/or normal tissues appear to be at least as appreciable in the endocervix as in the endometrium or cervical squamous epithelium. This raises that EZH2 staining might be applied as a differential diagnostic tool in endocervical lesions. At present, panels including
combinations of various markers are suggested for endocervical differential diagnosis. Sandra Lee et al. [26] showed that p16, p16/Ki67 dual stain, ProExC, CEA, ESA, HIK1083, Claudin 18, and ER losses in perilesional stromal cells were useful with high (≥0.75) sensitivity and specificity estimates in ≥1 malignant versus benign comparisons. Our data indicate that robust expression of EZH2 alone has an even higher diagnostic reliability, with a sensitivity and specificity of over 95%.

As a conclusion, EZH2 may play a role in the pathogenesis of endocervical neoplasia, and the detection of robust expression of EZH2 might be a useful differential diagnostic tool in problematic endocervical lesions in histology and probably in cytology as well.

Acknowledgments The authors gratefully acknowledge the Immunopathology Laboratory, Department of Pathology, University of Pécs and for their technical assistance. The present scientific certification is dedicated to the 650th anniversary of the foundation of the University of Pécs, Hungary.

Author contributions Evelin Makk played a major role in data collection and overview, interpreted the data, edited and revised the manuscript for intellectual content.

Levente Bálint played a major role in literary research, interpreted the data and revised the manuscript for intellectual content.

Fig. 3 Tuboendometrioid metaplasia (TEM) and tunnel cluster with HE. a1, b1 (a1, × 400 magnification; b1 × 300 magnification). a2 EZH2 negative staining in TEM (Table 3; Case No. 27; × 400 magnification). a3 Partly positive (robust) expression (+++) of EZH2 in another sample with TEM (Table 3; Case No. 28; × 400 magnification). b2 EZH2 negativity in tunnel cluster (Table 3; Case No. 30; × 300 magnification). b3 Partly positive (robust) expression (+++) of EZH2 in another case of tunnel cluster (Table 3; Case No. 31; × 300 magnification)
János Csífa played a major role in data collection, interpreted the data and revised the manuscript for intellectual content.

Tamás Tomóczyky played a major role in the design and conception of the work, interpreted the data and revised the manuscript for intellectual content.

Ángela Oszter played a major role in data analysis, interpreted the data, and revised the manuscript for intellectual content.

Arnold Tóth played a major role in statistical data analysis, interpreted the data, edited and revised the manuscript for intellectual content.

Kristína Kovács played a major role in the conception of the work, analyzed the data, interpreted the data, edited and revised the manuscript for intellectual content.

All authors approved the submitted manuscript and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Funding Information  Open access funding provided by University of Pécs (PTE).

Compliance with ethical standards

The use of patient data for the present study has been approved by the local ethical committee (number of permission: PTE/57682/2017).

Conflict of interest The authors declare that they have no conflict of interest.

Open Access  This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Karamurzin YS, Kiyokawa T, Parkash V, Jotwani AR, Patel P, Pike MC, Soslow RA, Park KJ (2015) Gastric-type endocervical adenocarcinoma: an aggressive tumor with unusual metastatic patterns and poor prognosis. Am J Surg Pathol 39(11):1449–1457. https://doi.org/10.1097/PAS.0000000000000532
2. Yokoi E, Mabuchi S, Takahashi R, Matsumoto Y, Kuroda H, Charpentier T, Kiyokawa T, Alvarado-Cabrero I, Pike MC, Soslow RA (2018) International Endocervical Adenocarcinoma Criteria and Classification (IECC): a new pathogenetic classification system. J Pathol 245(1):179–192. https://doi.org/10.1002/path.4750
3. Ronnett BM (2016) Endocervical adenocarcinoma: selected diagnostic challenges. Mod Pathol 29(Suppl 1):S12–S28. https://doi.org/10.1038/modpathol.2015.131
4. Guo CP, Liu KW, Luo HB, Chen HB, Zheng Y, Sun SN, Zhang Q, Huang L (2011) Potent anti-tumor effect generated by a novel human papillomavirus (HPV) antagonist peptide reactivating the pRB/E2F pathway. PLoS One 6(3):e17734. https://doi.org/10.1371/journal.pone.0017734
5. Huang SM, McCance DJ (2002) Down regulation of the interleukin-8 promoter by human papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and P/C/AF. J Virol 76(17):8710–8721
6. Zhang HM, Chen SQ, Yao SZ (2016) Expression and clinical implications of enhancer of Zeste homolog 2 and p53 protein in squamous cell carcinoma and precancerous lesions in the cervix. Genet Mol Res 15(2). https://doi.org/10.4238/gmr.15027408
7. Pourakbar S, Pluard TJ, Accordo AD, Farassati F (2017) Ezh2, a novel target in detection and therapy of breast cancer. Onco Targets Ther 10:2685–2687. https://doi.org/10.2147/OTT.S138777
8. Findeis-Hosey JJ, Huang J, Li F, Yang Q, McMahon LA, Xu H (2011) High-grade neuroendocrine carcinomas of the lung highly express enhancer of zeste homolog 2, but carcinoids do not. Hum Pathol 42(6):867–872. https://doi.org/10.1016/j.humpath.2010.09.019
9. Choi JH, Song YS, Yoon JS, Song KW, Lee YY (2010) Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer. APMIS 118(3):196–202. https://doi.org/10.1111/j.1600-0463.2009.02579.x
10. Fluge O, Gravdal K, Carlsen E, Vønen B, Kjellevold K, Refsum S, Lilleng R, Eide TJ, Halvorsen TB, Tveit KM, Otte AP, Akslen LA, Dahl O, Norwegian Gastrointestinal Cancer G (2009) Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. Br J Cancer 101(8):1282–1289. https://doi.org/10.1038/sj.bjc.6605333
11. Toll AD, Dasgupta A, Potoczak M, Yeo CJ, Cleare CG, Brody JR, Witkiewicz AK (2010) Implications of enhancer of zeste homolog 2 expression in pancreatic ductal adenocarcinoma. Hum Pathol 41(9):1205–1209. https://doi.org/10.1016/j.humpath.2010.03.004
12. Zhai R, Tang F, Gong J, Zhang J, Lei B, Li B, Wei Y, Liang X, Tang B, He S (2016) The relationship between the expression of USP22, BMI1, and EZH2 in hepatocellular carcinoma and their impacts on prognosis. Onco Targets Ther 9:6987–6998. https://doi.org/10.2147/OTT.S110985
13. Borbone E, Troncone G, Ferraro A, Jasencakova Z, Stojic L, Esposito F, Hornig N, Fusco A, Orlando V (2011) Enhancer of zeste homolog 2 overexpression has a role in the development of anaplastic thyroid carcinomas. J Clin Endocrinol Metab 96(4):1029–1038. https://doi.org/10.1210/jc.2010-1784
14. Abdelrahman AE, Arafa SA, Ahmed RA (2017) Prognostic value of Twist-1, E-cadherin and EZH2 in prostate cancer: an immunohistochemical study. Turk Patoloji Derg. https://doi.org/10.5146/tjpah.2017.01392
15. Raman JD, Mongan NP, Tickoo SK, Boorjian SA, Scherr DS, Gudas LJ (2005) Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res 11(24 Pt 1):8570–8576. https://doi.org/10.1158/1078-0432.CCR-05-1047
16. Zhou J, Roh JW, Bandyopadhyay S, Chen Z, Munkarah AR, Hussein Y, Alyosh B, Jazaerly T, Hayek K, Semaan A, Sood AK, Ali-Fehmi R (2013) Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma. Gynecol Oncol 127(2):344–348. https://doi.org/10.1016/j.ygyno.2012.07.128
17. Xu Y, Li X, Wang H, Xie P, Yan X, Bai Y, Zhang T (2016) Hypermethylation of CDH13, DKK3 and FOXL2 promoters and the expression of EZH2 in ovary granulosa cell tumors. Mol Med Rep 14(3):2739–2745. https://doi.org/10.3892/mmr.2016.5521
18. Jin M, Yang Z, Ye W, Yu X, Hua X (2015) Prognostic significance of histone methyltransferase enhancer of zeste homolog 2 in patients with cervical squamous cell carcinoma. Oncol Lett 10(2):857–862. https://doi.org/10.3892/ott.2015.3319
19. Stolnicu S, Barsan I, Huang L, Patel P, Terinte C, Pesci A, Aviel-Ronen S, Kiyokawa T, Alvarado-Cabrero I, Pike MC, Oliva E, Park KJ, Soslow RA (2018) International Endocervical Adenocarcinoma Criteria and Classification (IECC): a new pathogenetic
classification for invasive adenocarcinomas of the endocervix. Am J Surg Pathol 42(2):214–226. https://doi.org/10.1097/PAS.0000000000000986

20. Bosari S, Lee AK, Viale G, Heatley GJ, Coggi G (1992) Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up. Virchows Arch A Pathol Anat Histopathol 421(4):291–295

21. Shrout PE, Fleiss JL (1979) Intraclass correlations: uses in assessing rater reliability. Psychol Bull 86(2):420–428

22. Schoonjans F, Zalata A, Depuydt CE, Comhaire FH (1995) MedCalc: a new computer program for medical statistics. Comput Methods Prog Biomed 48(3):257–262

23. Koo TK, Li MY (2016) A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med 15(2):155–163. https://doi.org/10.1016/j.jcm.2016.02.012

24. Gu Y, Zhang J, Guan H (2017) Expression of EZH2 in endometrial carcinoma and its effects on proliferation and invasion of endometrial carcinoma cells. Oncol Lett 14(6):7191–7196. https://doi.org/10.3892/ol.2017.7171

25. Jia N, Li Q, Tao X, Wang J, Hua K, Feng W (2014) Enhancer of zeste homolog 2 is involved in the proliferation of endometrial carcinoma. Oncol Lett 8(5):2049–2054. https://doi.org/10.3892/ol.2014.2437

26. Lee S, Rose MS, Sahasrabuddhe VV, Zhao R, Duggan MA (2017) Tissue-based immunohistochemical biomarker accuracy in the diagnosis of malignant glandular lesions of the uterine cervix: a systematic review of the literature and meta-analysis. Int J Gynecol Pathol 36(4):310–322. https://doi.org/10.1097/PGP.0000000000000345

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.